A new study published in JAMA Internal Medicine found that capping monthly insulin spending at $35 for people with type 2 diabetes has been effective five years after it was first rolled out for Medicare patients. Researchers tracked 4.8 million people’s records before and after the ceiling was put in place and found that out-of-pocket spending fell significantly while insulin use went up.
The study revealed that blood sugar levels averaged over two to three months declined after the cap was implemented. However, there was a small increase in severe hypoglycemia events when blood sugar dropped too low. According to the study’s authors, these results were clearer than what has happened with some state programs, though they did not examine spending on other drugs, such as GLP-1s.
The impetus for the monthly spending limit stemmed from a significant price increase: insulin prices tripled from 2002 to 2013. Before the cap, financial barriers had prevented many people with type 2 diabetes from adhering to their treatment regimens, making affordability a critical component of managing the condition effectively.
The insulin cap represents one of the most direct policy interventions in recent years to address medication affordability in Medicare. By reducing out-of-pocket costs, the policy has made insulin treatment more accessible to vulnerable populations who depend on Medicare coverage, demonstrating that price controls can improve both medication adherence and health outcomes for people managing chronic conditions.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.statnews.com/2026/04/07/health-news-half-of-us-adults-are-aerobically-active-enough/